Table 2.
Observed AD Phenotype | Method | AD Source | Experimental Time Point, Days | Reference |
---|---|---|---|---|
Neurofibrillary tanglelike inclusions | Dual SMAD inhibition and Matrigel (Corning Life Sciences)—embedded 3D maturation | Application of recombinant human tau (K18) to P301L overexpressed neurons differentiated from NPCs | >28 | [116] |
Extracellular deposition of Aβ, including Aβ plaques Aggregates of pTau in the soma and neurites and filamentous tau |
Matrigel-embedded differentiation [137] | Lentiviral overexpression of FAD-related mutations in APP and PSEN1 of ReNcell VM (ReNeuron Group plc) | 49–100 | [118] |
Aβ42/Aβ40-correlated increase of pTau and cell death | Matrigel-embedded differentiation [138] | Lentiviral overexpression of FAD-related mutations in APP and PSEN1 of ReNcell VM and FACS purification | 35–84 | [119] |
Aβ accumulation and elevated pTau | Matrigel-embedded self-organized differentiation | FAD (APP and PSEN1) patient HiPSCs | 60–90 | [121] |
Aβ oligomers and Aβ aggregation | Hydrogel-embedded dual SMAD-inhibited differentiation [108] | FAD (APP and PSEN1) patient fibroblasts | >14 | [122] |
Aβ plaques Aggregated and abnormal pTau |
Component- and environment-controlled differentiation of cerebral organoids | FAD (PSEN1) and Down syndrome patient HiPSCs | 110 | [123] |
↑ Tau fragmentation and mislocalization Impaired axonal transport and functionality that can be improved by microtubule stabilization |
Matrigel-embedded self-organized differentiation | Familial frontotemporal dementia patient derived HiPSC with R406W mutation and isogenic control | 60 | [124] |
Accelerated neuronal differentiation ↑ Synaptic markers ↑ Total tau and pTau |
Matrigel-embedded growth factor–directed differentiation of HiPSCs in spinning bioreactor | apoE4+ LOAD patient–derived fibroblasts and gene-edited (apoE4) healthy control–derived fibroblasts | 46 | [128] |
Early neuronal differentiation Aβ accumulation and elevated pTau |
Matrigel-embedded self-organized differentiation | HiPSCs from LOAD patients with apoE4 mutation | >180 | [89] |
↑ Secretion of long Aβ peptides (Aβ40, Aβ42, and Aβ43) | Matrigel-embedded growth factor–directed differentiation of HiPSCs in spinning bioreactor | Fibroblasts from FAD patients with FAD-linked mutations in APP or PSEN1 | 100 | [125] |
Increased Aβ42/Aβ40 peptide ratios and decreased synaptic protein levels | Matrigel-embedded differentiation in suspension | FAD (APP and PSEN1) patient HiPSCs | 35 | [130] |
Aβ, amyloid-β; AD, Alzheimer’s disease; apoE4, apolipoprotein E4; APP, amyloid precursor protein; FACS, fluorescence-activated cell sorting; FAD, familial AD; HiPSC, human induced pluripotent stem cell; LOAD, late-onset AD; NPC, neural progenitor cell; PSEN1, presenilin 1; pTau, phosphorylated tau; SMAD, an acronym from the fusion of the Caenorhabditis elegans and Drosophila genes, Sma and Mad (mothers against decapentaplegic); 3D, 3-dimensional.